Irritable Bowel Syndrome - Budesonide.

Budesonide as treatment for patients with irritable bowel syndrome.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON28758

Enrollment

Registered

2005-05-31

Start date

2005-04-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

3 mg Budesonide TID or placebo for 2 months

Eligibility

Inclusion criteria

Inclusion criteria: Fulfilling Rome II criteria of IBS, 18-65 years of age, no other organic abnormalities explaining the complaints.

Exclusion criteria

Exclusion criteria: Severe comorbidity, pregnancy/lactation.

Design outcomes

Primary

Measure	Time frame
The effect of budesonide on the rectal sensitivity in IBS. Participants are treated with budesonide 3 dd 3 mg or placebo during eight weeks. To assess the rectal sensitivity a barostat investigation is performed before and after the treatment-period.	—

Secondary

Measure	Time frame
The effect of budesonide on inflammation in rectal biopsy specimen and the effect of budesonide on IBS-symptoms.	—

Contacts

Public ContactG.E.E. Boeckxstaens

Academic Medical Center (AMC), Department of Gastroenterology, C2-328, P.O. Box 22660

g.e.boeckxstaens@amc.uva.nl+31 (0)20 5667375

Outcome results